Positions

Selected Publications

Academic Article

Year Title Altmetric
2021 Cannabidiol (CBD) and cognition in epilepsyEpilepsy and Behavior.  124. 2021
2021 Pharmacogenetic Predictors of Cannabidiol Response and Tolerability in Treatment-Resistant EpilepsyClinical Pharmacology and Therapeutics.  110:1368-1380. 2021
2021 Longitudinal impact of cannabidiol on EEG measures in subjects with treatment-resistant epilepsyEpilepsy and Behavior.  122. 2021
2021 White matter integrity after cannabidiol administration for treatment resistant epilepsyJournal of epilepsy.  172. 2021
2021 Long-term safety and efficacy of highly purified cannabidiol for treatment refractory epilepsyEpilepsy and Behavior.  117. 2021
2020 Cannabidiol normalizes resting-state functional connectivity in treatment-resistant epilepsyEpilepsy and Behavior.  112. 2020
2020 Effects of highly purified cannabidiol (CBD) on fMRI of working memory in treatment-resistant epilepsyEpilepsy and Behavior.  112. 2020
2020 White matter and neurite morphology differ in psychogenic nonepileptic seizuresAnnals of Clinical and Translational Neurology.  7:1973-1984. 2020
2020 De Novo Status Epilepticus in patients with COVID-19Annals of Clinical and Translational Neurology.  7:1240-1244. 2020
2019 Drug–drug interactions with cannabidiol (CBD) appear to have no effect on treatment response in an open-label Expanded Access ProgramEpilepsy and Behavior.  98:201-206. 2019
2019 Cognitive functioning following long-term cannabidiol use in adults with treatment-resistant epilepsyEpilepsy and Behavior.  97:105-110. 2019
2019 fMRI study of cannabidiol-induced changes in attention control in treatment-resistant epilepsyEpilepsy and Behavior.  96:114-121. 2019
2019 Higher cannabidiol plasma levels are associated with better seizure response following treatment with a pharmaceutical grade cannabidiolEpilepsy and Behavior.  95:131-136. 2019
2019 Quality of life in adults enrolled in an open-label study of cannabidiol (CBD) for treatment-resistant epilepsyEpilepsy and Behavior.  95:10-17. 2019
2019 A preliminary study of the effects of cannabidiol (CBD) on brain structure in patients with epilepsy 2019
2019 Memory response and neuroimaging correlates of a novel cognitive rehabilitation program for memory problems in epilepsy: A pilot studyRestorative Neurology and Neuroscience.  37:457-468. 2019
2018 Cannabis for the Treatment of Epilepsy: an UpdateCurrent Neurology and Neuroscience Reports.  18. 2018
2018 Cannabidiol improves frequency and severity of seizures and reduces adverse events in an open-label add-on prospective studyEpilepsy and Behavior.  87:131-136. 2018
2018 Cannabidiol improves frequency and severity of seizures and reduces adverse events in an open-label add-on prospective study Pongkiat Kankirawatana, Dr Rani Singh, Professor David G Standaert, Dr Yuliang Liu, Dr Leon Dure, Dr Jennifer DeWollfe, Professor Gary Cutter, Dr Tyler Gaston, Dr Ashley Thomas, Professor E. Martina Bebin, Dr. Lawrence Ver HoefEpilepsy and Behavior.  (in press). 2018
2017 Interactions between cannabidiol and commonly used antiepileptic drugsEpilepsia.  58:1586-1592. 2017
2017 Pharmacology of cannabinoids in the treatment of epilepsyEpilepsy and Behavior.  70:313-318. 2017
2016 Which patients with epilepsy are at risk for psychogenic nonepileptic seizures (PNES)? A multicenter case–control studyEpilepsy and Behavior.  61:180-184. 2016
2016 White matter abnormalities in patients with treatment-resistant genetic generalized epilepsies 2016
2015 White matter diffusion abnormalities in patients with psychogenic non-epileptic seizuresBrain Research.  1620:169-176. 2015

Education And Training

  • University of Alabama, Internship
  • University of Alabama at Birmingham, Residency
  • University of Alabama, Postdoctoral Fellowship
  • Doctor of Medicine, University of South Alabama 2011
  • Full Name

  • Tyler Gaston